Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/9/2025

Management of Metastatic Prostate Cancer

Introduction to Treatment

  • The European Association of Urology recommends androgen deprivation therapy as the first-line treatment for metastatic castration-sensitive prostate cancer, according to the European Association of Urology 1, 2
  • When initiating LHRH agonists, a short-course antiandrogen should be administered to prevent the "flare" phenomenon caused by the initial increase in testosterone, as suggested by the European Association of Urology 1, 3

Systemic Primary Treatment

  • Androgen deprivation therapy should be continued even if the disease progresses to castration-resistant state, as recommended by the European Association of Urology 3

Bone Protection

  • Denosumab or zoledronic acid is recommended for patients with castration-resistant prostate cancer and bone metastases at high risk of skeletal-related events, according to the European Association of Urology 2
  • Zoledronic acid 4 mg intravenously every 3-4 weeks is approved to prevent skeletal complications (pathological fractures, spinal cord compression, surgery, or radiation to bone), as recommended by the National Comprehensive Cancer Network 6

Symptom Management

  • For painful bone metastases, a single fraction of 8 Gy is equally effective as 10 fractions of 3 Gy for pain relief and is more cost-effective, as recommended by the National Comprehensive Cancer Network 3
  • Radio-223 is indicated for patients with symptomatic bone metastases without known visceral disease, significantly improving overall survival (median 14.9 vs 11.3 months), according to the European Association of Urology 3

Palliative Care and Quality of Life

  • Patients with castration-resistant prostate cancer should be managed in collaboration with dedicated palliative care services, as recommended by the American Society of Clinical Oncology 9, 3
  • Early access to symptom palliation specialists is recommended for men with castration-resistant prostate cancer, according to the European Association of Urology 9

Future Options if Progression to Castration Resistance

  • Chemotherapy with docetaxel is appropriate for symptomatic patients with good performance status and should be discussed with asymptomatic patients with evidence of rapid progression, as recommended by the European Association of Urology 2

Monitoring and Follow-up

  • In men with castration-resistant prostate cancer, staging examinations, including imaging, should be performed before each new line of treatment, as recommended by the European Association of Urology 9
  • Regular monitoring with imaging is recommended for men with castration-resistant prostate cancer, according to the European Association of Urology 9

Special Considerations for Comorbidities

  • This patient requires comprehensive management of pre-existing comorbidities, including optimization of hypertension, control of diabetes, management of chronic kidney disease, correction of anemia, urgent nutritional intervention, and exercise and rehabilitation program, as recommended by the European Association of Urology 8